Literature DB >> 17442335

Production and characterization of monoclonal antibodies against complexes of the NKT cell ligand alpha-galactosylceramide bound to mouse CD1d.

Karl O A Yu1, Jin S Im, Petr A Illarionov, Rachel M Ndonye, Amy R Howell, Gurdyal S Besra, Steven A Porcelli.   

Abstract

The alpha-galactosylceramide (alpha-GalCer) known as KRN7000 remains the best studied ligand of the lipid-binding MHC class I-like protein CD1d. The KRN7000:CD1d complex is highly recognized by invariant natural killer T (iNKT) cells, an evolutionarily conserved subset of T lymphocytes that express an unusual semi-invariant T cell antigen receptor, and mediate a variety of proinflammatory and immunoregulatory functions. To facilitate the study of glycolipid antigen presentation to iNKT cells by CD1d, we undertook the production of mouse monoclonal antibodies (mAbs) specific for complexes of KRN7000 bound to mouse CD1d (mCD1d) proteins. Three such monoclonal antibodies were isolated that bound only to mCD1d proteins that were loaded with KRN7000 or closely-related forms of alpha-GalCer. These mAbs showed no reactivity with mCD1d proteins that were not loaded with alpha-GalCer, nor did they bind to complexes formed by loading mCD1d with the self-glycolipid and putative iNKT cell ligand isoglobotrihexosylceramide. These complex-specific monoclonal antibodies allow the direct detection and monitoring of complexes formed by the binding of KRN7000 and other alpha-GalCer analogues to mCD1d. The availability of these mAbs should facilitate a wide range of studies on the biology and potential clinical applications of CD1d-restricted iNKT cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17442335      PMCID: PMC1939826          DOI: 10.1016/j.jim.2007.03.006

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  30 in total

1.  Mouse CD1-autoreactive T cells have diverse patterns of reactivity to CD1+ targets.

Authors:  L Brossay; S Tangri; M Bix; S Cardell; R Locksley; M Kronenberg
Journal:  J Immunol       Date:  1998-04-15       Impact factor: 5.422

2.  Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody.

Authors:  A Porgador; J W Yewdell; Y Deng; J R Bennink; R N Germain
Journal:  Immunity       Date:  1997-06       Impact factor: 31.745

3.  Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides.

Authors:  Karl O A Yu; Jin S Im; Alberto Molano; Yves Dutronc; Petr A Illarionov; Claire Forestier; Nagatoshi Fujiwara; Isa Arias; Sachiko Miyake; Takashi Yamamura; Young-Tae Chang; Gurdyal S Besra; Steven A Porcelli
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-18       Impact factor: 11.205

4.  Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections.

Authors:  Jochen Mattner; Kristin L Debord; Nahed Ismail; Randal D Goff; Carlos Cantu; Dapeng Zhou; Pierre Saint-Mezard; Vivien Wang; Ying Gao; Ning Yin; Kasper Hoebe; Olaf Schneewind; David Walker; Bruce Beutler; Luc Teyton; Paul B Savage; Albert Bendelac
Journal:  Nature       Date:  2005-03-24       Impact factor: 49.962

5.  Recognition of bacterial glycosphingolipids by natural killer T cells.

Authors:  Yuki Kinjo; Douglass Wu; Gisen Kim; Guo-Wen Xing; Michael A Poles; David D Ho; Moriya Tsuji; Kazuyoshi Kawahara; Chi-Huey Wong; Mitchell Kronenberg
Journal:  Nature       Date:  2005-03-24       Impact factor: 49.962

6.  CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides.

Authors:  T Kawano; J Cui; Y Koezuka; I Toura; Y Kaneko; K Motoki; H Ueno; R Nakagawa; H Sato; E Kondo; H Koseki; M Taniguchi
Journal:  Science       Date:  1997-11-28       Impact factor: 47.728

7.  Mouse CD1 is mainly expressed on hemopoietic-derived cells.

Authors:  L Brossay; D Jullien; S Cardell; B C Sydora; N Burdin; R L Modlin; M Kronenberg
Journal:  J Immunol       Date:  1997-08-01       Impact factor: 5.422

8.  CD1.1 expression by mouse antigen-presenting cells and marginal zone B cells.

Authors:  J H Roark; S H Park; J Jayawardena; U Kavita; M Shannon; A Bendelac
Journal:  J Immunol       Date:  1998-04-01       Impact factor: 5.422

9.  Diverse TCRs recognize murine CD1.

Authors:  S M Behar; T A Podrebarac; C J Roy; C R Wang; M B Brenner
Journal:  J Immunol       Date:  1999-01-01       Impact factor: 5.422

10.  CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells.

Authors:  F M Spada; Y Koezuka; S A Porcelli
Journal:  J Exp Med       Date:  1998-10-19       Impact factor: 14.307

View more
  34 in total

1.  The identification of the endogenous ligands of natural killer T cells reveals the presence of mammalian α-linked glycosylceramides.

Authors:  Lisa Kain; Bill Webb; Brian L Anderson; Shenglou Deng; Marie Holt; Anne Costanzo; Anne Constanzo; Meng Zhao; Kevin Self; Anais Teyton; Chris Everett; Mitchell Kronenberg; Dirk M Zajonc; Albert Bendelac; Paul B Savage; Luc Teyton
Journal:  Immunity       Date:  2014-10-16       Impact factor: 31.745

2.  Development of spontaneous anergy in invariant natural killer T cells in a mouse model of dyslipidemia.

Authors:  Nicole A Braun; Yanice V Mendez-Fernandez; Roman Covarrubias; Steven A Porcelli; Paul B Savage; Hideo Yagita; Luc Van Kaer; Amy S Major
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-06-10       Impact factor: 8.311

3.  Structural basis for the recognition of C20:2-αGalCer by the invariant natural killer T cell receptor-like antibody L363.

Authors:  Esther Dawen Yu; Enrico Girardi; Jing Wang; Thien-Thi Mac; Karl O A Yu; Serge Van Calenbergh; Steven A Porcelli; Dirk M Zajonc
Journal:  J Biol Chem       Date:  2011-11-22       Impact factor: 5.157

Review 4.  Harnessing invariant NKT cells in vaccination strategies.

Authors:  Vincenzo Cerundolo; Jonathan D Silk; S Hajar Masri; Mariolina Salio
Journal:  Nat Rev Immunol       Date:  2009-01       Impact factor: 53.106

5.  Analyzing antigen recognition by Natural Killer T cells.

Authors:  Sebastian Zeissig; Torsten Olszak; Espen Melum; Richard S Blumberg
Journal:  Methods Mol Biol       Date:  2013

6.  Dendritic cells tolerized with adenosine A₂AR agonist attenuate acute kidney injury.

Authors:  Li Li; Liping Huang; Hong Ye; Steven P Song; Amandeep Bajwa; Sang Ju Lee; Emily K Moser; Katarzyna Jaworska; Gilbert R Kinsey; Yuan J Day; Joel Linden; Peter I Lobo; Diane L Rosin; Mark D Okusa
Journal:  J Clin Invest       Date:  2012-10-24       Impact factor: 14.808

7.  The BTB-zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions.

Authors:  Damian Kovalovsky; Olisambu U Uche; Sonia Eladad; Robin M Hobbs; Woelsung Yi; Eric Alonzo; Kevin Chua; Maggie Eidson; Hye-Jung Kim; Jin S Im; Pier Paolo Pandolfi; Derek B Sant'Angelo
Journal:  Nat Immunol       Date:  2008-07-27       Impact factor: 25.606

8.  A CD1d-dependent antagonist inhibits the activation of invariant NKT cells and prevents development of allergen-induced airway hyperreactivity.

Authors:  Vincent Lombardi; Philippe Stock; Abinav K Singh; Jerome Kerzerho; Wen Yang; Barbara A Sullivan; Xiangming Li; Takayuki Shiratsuchi; Nathan E Hnatiuk; Amy R Howell; Karl O A Yu; Steven A Porcelli; Moriya Tsuji; Mitchell Kronenberg; S Brian Wilson; Omid Akbari
Journal:  J Immunol       Date:  2010-01-18       Impact factor: 5.422

9.  Immunologic glycosphingolipidomics and NKT cell development in mouse thymus.

Authors:  Yunsen Li; Prakash Thapa; David Hawke; Yuji Kondo; Keiko Furukawa; Koichi Furukawa; Fong-Fu Hsu; Dietlind Adlercreutz; Joel Weadge; Monica M Palcic; Peng G Wang; Steven B Levery; Dapeng Zhou
Journal:  J Proteome Res       Date:  2009-06       Impact factor: 4.466

10.  Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation.

Authors:  Jin S Im; Pooja Arora; Gabriel Bricard; Alberto Molano; Manjunatha M Venkataswamy; Ian Baine; Elliot S Jerud; Michael F Goldberg; Andres Baena; Karl O A Yu; Rachel M Ndonye; Amy R Howell; Weiming Yuan; Peter Cresswell; Young-Tae Chang; Petr A Illarionov; Gurdyal S Besra; Steven A Porcelli
Journal:  Immunity       Date:  2009-06-19       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.